A Study of PF-04217903 in Patients With Advanced Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-08-31

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PF-04217903 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-04217903 is a new member in a class of drugs called c-Met/hepatocyte growth factor receptor tyrosine kinase inhibitors. This research study is the first time PF-04217903 will be given to patients. PF-04217903 is taken by mouth daily.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Of PF-06647263 In Patients With Advanced Solid Tumors

NCT02078752

Neoplasms Triple-Negative Breast Cancer

TERMINATED PHASE1

A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors

NCT00557856

Advanced Solid Tumors

COMPLETED PHASE1

A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients

NCT00927823

Cancer

COMPLETED PHASE1

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

NCT04628780

Non-small-cell Lung Cancer Squamous Cell Carcinoma of the Head and Neck Renal Cell Carcinoma +3 more

TERMINATED PHASE1

A Study Of PF-03732010 In Patients With Advanced Solid Tumors

NCT00557505

Neoplasms

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study was prematurely discontinued due to a strategic development decision by Pfizer on 10FEB2012. The decision to terminate was not based on any safety concerns.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

PF-04217903

Intervention Type DRUG

Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-04217903

Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Advanced solid tumors, histologically proven at diagnosis which is refractory to standard of care or for whom no standard of care therapy is available
* Adequate blood cell counts, normal kidney function, and performance status of 0 or 1

Exclusion Criteria

* Major surgery, radiation therapy or anti-cancer therapy within 2 weeks of starting study treatment
* Prior stem cell transplant
* Active or unstable cardiac disease or heart attack within 12 months of starting study treatment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No